Table of Contents
US demand to increase 6.1% annually through 2019
US demand for pharmaceutical chemicals is forecast to rise 6.1 percent annually to $54 billion in 2019. Merchant market sales primarily to generic drug companies will account for nearly one-third of this total. The remainder of demand will consist of the value of pharmaceutical chemicals produced captively or con¬tracted for internal use by makers of proprietary drugs.
New therapies to drive captive & contract market
Although moderated by patent losses, the value of pharmaceutical chemicals obtained from captive and contract production systems will sustain favorable growth, expanding 5.3 percent annually to $36.7 billion in 2019. The introduction of new therapies with enhanced efficacy will underlie gains. For example, in 2014, a total of 41 new molecular entities were approved for marketing by the Food and Drug Administration. Among these approvals were several breakthrough therapies, including blinatumomab for acute lymphoblastic leukemia, ceritinib for late-stage non-small cell lung cancer, ledipasvir/sofosbuvir for chronic hepatitis C, nintedanib and pirfenidone for idiopathic pulmonary fibrosis, and nivolumab for metastatic melanoma. In addition to new molecular entities, growth prospects for proprietary pharma¬ceutical chemicals will benefit from a number of recent prescription to over-the-counter switches, which extended commercial protection on non-prescrip¬tion versions of compounds such as esomeprazole magnesium and fluticasone proprionate.
Merchant market demand to grow nearly 8% per annum
Based on the impact of recent and forth-coming drug patent expirations and the expansion of the generic drug industry, merchant market demand for pharmaceu¬tical chemicals will increase 7.8 percent per year to $17.3 billion in 2019. Gains will reflect the introduction and rapid market penetration of generic versions of several blockbuster drugs. Among the pharmaceutical chemicals projected to generate impressive growth in merchant sales due to patent expirations are aripi-prazole for bipolar disorder; capecitabine for metastatic breast and colorectal cancer; celecoxib for arthritis; duloxitine HCl for depression, generalized anxiety, and chronic pain; eszopiclone for insomnia; glatiramer acetate for multiple sclerosis; oxycodone HCl for pain management; and raloxifene HCl for osteoporosis.
This upcoming industry study, Pharmaceutical Chemicals, presents historical demand data (2004, 2009, 2014) plus forecasts (2019, 2024) by type of active pharmaceutical ingredient (API) and raw material. The study also considers key market environment factors, assesses the industry structure, evaluates company market share, and profiles 51 participants in the US industry.
Get Industry Insights. Simply.
Talk to Ahmad
+1 718 618 4302
The global specialty chemicals market was valued at USD XX billion in 2015, and is likely to reach USD XX billion by 2020, growing at a CAGR of XX%, during the forecast period (2017 - 2022). Specialty ...
Use this report to: - Assess global market and quantify the demands for flame retardant chemicals by chemical type and end-use application over the years 2016 to 2022. - l Understand current market dynamics ...
“Global paints & coatings market to register a CAGR of 5.07% from 2016 to 2021” The global paints & coatings market was valued at USD 141.58 billion in 2015 and is projected to register a CAGR of ...